Immunotherapy

1. Gene symbol

 

2. Response

Combined response (n=1,434)

3. Treatment

Anti PD-1 (CD279) therapy

any anti PD-1

nivolumab

pembrolizumab

Anti PD-L1 (CD274) therapy

any anti PD-L1

atezolizumab

durvalumab

Anti CTLA4 (CD152) therapy

any anti CTLA-4

ipilimumab

Any

any immune checkpoint inhibitor therapy

Total: 0

Non-responders: 0

Responders: 0

4. Filters (optional)

Sample acquisition All Pretreatment(n = 1267) Ontreatment (n = 167)

Gender All Male (n = 801) Female (n = 350)

Primary tumor All No (n = 164) Yes (n = 552)

Metastatic All No (n = 120) Yes (n = 988)

5. Settings

Tissue of origin Glioblastoma Hepatocellular Carcinoma Colorectal Non Squamous Lung Cancer Small Cell Lung Cancer Esophageal Adeno Head And Neck Squamous Cell Carcinoma Ureter/ Renal Pelvis Urothelial Non Small Cell Lung Cancer Melanoma Bladder Breast Renal Cell Carcinoma Squamous Lung Cancer Gastric Cancer All

No outliers

Show quartiles

Multi-gene analysis

Calculate

By using the services, you agree to be bound by the Terms of Use.

Please kindly cite our paper to support further development: Kovacs SA, Fekete JT, Gyorffy B.: Predictive biomarkers of immunotherapy response with pharmacological applications in solid tumors , Acta Pharmacol Sin., 2023 Apr 13.;doi: 10.1038/s41401-023-01079-6.